The Difference is in the Data®
Strong science, strength of process, and a sense of urgency, MMS is redefining the CRO experience.
& Medical Writing
Helping sponsors navigate a complex regulatory environment
MMS is an award-winning, data-focused clinical research organization (CRO) that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards.
Industry experts across 4 continents are available to support your programs 24×7 with a 97 percent sponsor satisfaction rating
“MMS is the only company I would reach out to, big or small. MMS understood and worked within our capabilities and with our unconventional strategies we were forced into by the nature of being small and underfunded. Your team worked with us, diligently, beyond expectations, and got us over the finish line to success.”
—Sr. Vice President, Research & Development, Small Pharma
“This team never stopped working towards our deadline, and from day one, we were impressed with the efficient and smart decisions brought forth by MMS to bring this drug to market.”
—Randy Brenner, Senior Vice President Global Regulatory Affairs, Quality, and Technical Operations, Paratek
“We work with a lot of CROs and consultants here in Boston. They’re good, they do fine, but you guys are the standard.”
— Senior Director, Clinical Quality Assurance, Large Pharma
“MMS consistently provides our team with the highest level of detail and quality work in every task that they undertake. I am pleased that we were able to attain this fast track status and look forward to working with MMS as we continue into the phase three studies.”
— Dr. Doo Lee, CEO and Head of Research and Development, Vivozon
“The choice in collaborating with MMS to meet this milestone… was simple, given their deep scientific knowledge and strategic resource models,”
— Dr. Steven Gullans, CEO, Gemphire
Register for an upcoming webinar for detailed and actionable insights
The Expert Insights webinar series from MMS Holdings offers complimentary learning opportunities on current trends, high-value topics, and complex initiatives in the evolving pharmaceutical, biotechnology, and medical device industries. Review our upcoming topics or register here!
Submission Support for Paratek Pharmaceuticals Garners FDA Approval and Successful MAA Filing
MMS supported Paratek Pharmaceuticals, Inc. for the new drug application (NDA) approval and successful marketing authorisation application (MAA) filing of NUZYRA™ (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). Get the details
MMS joins decentralized trials & research alliance (DTRA)
MMS joined a historic alliance of 50 life sciences organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. The DTRA plans to unite industry stakeholders, including healthcare companies, regulators, patient groups and research organizations with a singular mission to make clinical trial participation widely accessible by advancing policies, research practices, and new technologies in decentralized clinical research. Read more
MMS WINS AWARD FOR MOST INNOVATIVE CLINICAL RESEARCH ORGANIZATION
In a recent awards program, MMS has been recognized as the Most Innovative Clinical Research Organization (CRO) in the United States. During the annoncement, we shared that “Innovation is everyone’s responsibility at MMS, and our sense of urgency and leadership (SOUL) philosophy continues to guide this direction.” Learn more